263 related articles for article (PubMed ID: 29079454)
1. The adenosine A
Ferrante A; Pezzola A; Matteucci A; Di Biase A; Attorri L; Armida M; Martire A; Chern Y; Popoli P
Neurobiol Dis; 2018 Feb; 110():1-11. PubMed ID: 29079454
[TBL] [Abstract][Full Text] [Related]
2. Stimulation of adenosine A2A receptors reduces intracellular cholesterol accumulation and rescues mitochondrial abnormalities in human neural cell models of Niemann-Pick C1.
Ferrante A; De Nuccio C; Pepponi R; Visentin S; Martire A; Bernardo A; Minghetti L; Popoli P
Neuropharmacology; 2016 Apr; 103():155-62. PubMed ID: 26631535
[TBL] [Abstract][Full Text] [Related]
3. The stimulation of adenosine A2A receptors ameliorates the pathological phenotype of fibroblasts from Niemann-Pick type C patients.
Visentin S; De Nuccio C; Bernardo A; Pepponi R; Ferrante A; Minghetti L; Popoli P
J Neurosci; 2013 Sep; 33(39):15388-93. PubMed ID: 24068806
[TBL] [Abstract][Full Text] [Related]
4. Adenosine A
De Nuccio C; Bernardo A; Ferrante A; Pepponi R; Martire A; Falchi M; Visentin S; Popoli P; Minghetti L
Sci Rep; 2019 Jul; 9(1):9782. PubMed ID: 31278313
[TBL] [Abstract][Full Text] [Related]
5. Systemic AAV9 gene therapy improves the lifespan of mice with Niemann-Pick disease, type C1.
Chandler RJ; Williams IM; Gibson AL; Davidson CD; Incao AA; Hubbard BT; Porter FD; Pavan WJ; Venditti CP
Hum Mol Genet; 2017 Jan; 26(1):52-64. PubMed ID: 27798114
[TBL] [Abstract][Full Text] [Related]
6. A novel mouse model of Niemann-Pick type C disease carrying a D1005G-Npc1 mutation comparable to commonly observed human mutations.
Maue RA; Burgess RW; Wang B; Wooley CM; Seburn KL; Vanier MT; Rogers MA; Chang CC; Chang TY; Harris BT; Graber DJ; Penatti CA; Porter DM; Szwergold BS; Henderson LP; Totenhagen JW; Trouard TP; Borbon IA; Erickson RP
Hum Mol Genet; 2012 Feb; 21(4):730-50. PubMed ID: 22048958
[TBL] [Abstract][Full Text] [Related]
7. Myelin Defects in Niemann-Pick Type C Disease: Mechanisms and Possible Therapeutic Perspectives.
Bernardo A; De Nuccio C; Visentin S; Martire A; Minghetti L; Popoli P; Ferrante A
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445564
[TBL] [Abstract][Full Text] [Related]
8. Geranylgeranyl pyrophosphate is crucial for neuronal survival but has no special role in Purkinje cell degeneration in Niemann Pick type C1 disease.
Marschalek N; Albert F; Afshordel S; Meske V; Eckert GP; Ohm TG
J Neurochem; 2015 Apr; 133(1):153-61. PubMed ID: 25319340
[TBL] [Abstract][Full Text] [Related]
9. Npc1 deficiency in the C57BL/6J genetic background enhances Niemann-Pick disease type C spleen pathology.
Parra J; Klein AD; Castro J; Morales MG; Mosqueira M; Valencia I; Cortés V; Rigotti A; Zanlungo S
Biochem Biophys Res Commun; 2011 Sep; 413(3):400-6. PubMed ID: 21910975
[TBL] [Abstract][Full Text] [Related]
10. Developmental delay in motor skill acquisition in Niemann-Pick C1 mice reveals abnormal cerebellar morphogenesis.
Caporali P; Bruno F; Palladino G; Dragotto J; Petrosini L; Mangia F; Erickson RP; Canterini S; Fiorenza MT
Acta Neuropathol Commun; 2016 Sep; 4(1):94. PubMed ID: 27586038
[TBL] [Abstract][Full Text] [Related]
11. Intracerebroventricular Treatment with 2-Hydroxypropyl-β-Cyclodextrin Decreased Cerebellar and Hepatic Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Expression in Niemann-Pick Disease Type C Model Mice.
Fukaura M; Ishitsuka Y; Shirakawa S; Ushihama N; Yamada Y; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kurauchi Y; Seki T; Katsuki H; Higaki K; Matsuo M; Irie T
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33466390
[TBL] [Abstract][Full Text] [Related]
12. Pneumococcal Immunization Reduces Neurological and Hepatic Symptoms in a Mouse Model for Niemann-Pick Type C1 Disease.
Houben T; Magro Dos Reis I; Oligschlaeger Y; Steinbusch H; Gijbels MJJ; Hendrikx T; Binder CJ; Cassiman D; Westerterp M; Prickaerts J; Shiri-Sverdlov R
Front Immunol; 2018; 9():3089. PubMed ID: 30666257
[TBL] [Abstract][Full Text] [Related]
13. In Niemann-Pick C1 mouse models, glial-only expression of the normal gene extends survival much further than do changes in genetic background or treatment with hydroxypropyl-beta-cyclodextrin.
Marshall CA; Watkins-Chow DE; Palladino G; Deutsch G; Chandran K; Pavan WJ; Erickson RP
Gene; 2018 Feb; 643():117-123. PubMed ID: 29223359
[TBL] [Abstract][Full Text] [Related]
14. Gene Therapy in a Mouse Model of Niemann-Pick Disease Type C1.
Kurokawa Y; Osaka H; Kouga T; Jimbo E; Muramatsu K; Nakamura S; Takayanagi Y; Onaka T; Muramatsu SI; Yamagata T
Hum Gene Ther; 2021 Jun; 32(11-12):589-598. PubMed ID: 33256498
[TBL] [Abstract][Full Text] [Related]
15. Single Cell Transcriptome Analysis of Niemann-Pick Disease, Type C1 Cerebella.
Cougnoux A; Yerger JC; Fellmeth M; Serra-Vinardell J; Martin K; Navid F; Iben J; Wassif CA; Cawley NX; Porter FD
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32731618
[TBL] [Abstract][Full Text] [Related]
16. Genetic background modifies phenotypic severity and longevity in a mouse model of Niemann-Pick disease type C1.
Rodriguez-Gil JL; Watkins-Chow DE; Baxter LL; Elliot G; Harper UL; Wincovitch SM; Wedel JC; Incao AA; Huebecker M; Boehm FJ; Garver WS; Porter FD; Broman KW; Platt FM; Pavan WJ
Dis Model Mech; 2020 Mar; 13(3):. PubMed ID: 31996359
[TBL] [Abstract][Full Text] [Related]
17. Pregnane X receptor (PXR) activation: a mechanism for neuroprotection in a mouse model of Niemann-Pick C disease.
Langmade SJ; Gale SE; Frolov A; Mohri I; Suzuki K; Mellon SH; Walkley SU; Covey DF; Schaffer JE; Ory DS
Proc Natl Acad Sci U S A; 2006 Sep; 103(37):13807-12. PubMed ID: 16940355
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein amplification improves cerebellar myelination in the Npc1
Gray J; Fernández-Suárez ME; Falah M; Smith D; Smith C; Kaya E; Palmer AM; Fog CK; Kirkegaard T; Platt FM
EBioMedicine; 2022 Dec; 86():104374. PubMed ID: 36455410
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy with cyclodextrin/allopregnanolone and miglustat improves motor but not cognitive functions in Niemann-Pick Type C1 mice.
Hovakimyan M; Maass F; Petersen J; Holzmann C; Witt M; Lukas J; Frech MJ; Hübner R; Rolfs A; Wree A
Neuroscience; 2013 Nov; 252():201-11. PubMed ID: 23948640
[TBL] [Abstract][Full Text] [Related]
20. Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin.
Cougnoux A; Clifford S; Salman A; Ng SL; Bertin J; Porter FD
Mol Genet Metab; 2018 Dec; 125(4):345-350. PubMed ID: 30392741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
